Crowdacure and the Peer Review


How Does it Work?

Funding medical research is very competitive. Every project requires a significant amount of money, 
yet the available funds are limited. When deciding what research will get the grant, the first 
criterion is what are the priorities of the funding organisation, its agenda. Other key elements are the 
scientific and medical quality of the project and the research team. Traditionally, the organisation giving 
the grant will ask peer experts (experts in the particular relevant field of research) to review the project 
for them- hence Peer Review. Crowdacure follows the same procedure and works with experts to make sure the 
projects campaigning on the platform are of good scientific and medical quality (see below). 

The candidate researchers will submit to Crowdacure Reviewers the documentation of the review 
they have been through or alternatively the necessary information to undergo the peer-review 
by the experts of Crowdacure. 

The experts reviewing the research projects will make sure:

- they are fit to be funded (fundable): they are of good medical and scientific quality or
- that they eventually have been peer-reviewed appropriately elsewhere  
- that the projects are hard to fund or researching a field of medicine where funding is insufficient  

The Reviewers:

Funding medical research is a challenging and complex process that few 
people are informed of. 
It  requires not only medical and scientific expertise, but also knowledge on research in general, 
research funding ethics and funding mechanisms. 
Each organisation funding medical research works with a committee of reviewers, who are experts 
in their field of medical research. They must be independent in their review, independent of the 
work they review and independent of the funding organisation, to ensure their opinion is impartial.
They are experts, peers to the applicants, which is why it is called peer-review.

Funding Hardship & Underfunded Status
Crowdacure is a platform dedicated to hard to fund and underfunded medical research.
Therefore, the peer review will also assess the funding hardship.


It is common that medical research projects are covered by more than one grants, as they 
require a significant amount of money. Therefore, together with the research team, the 
CROWDACURE PRC role will also include determining a mini-goal, which is the minimum reasonable 
amount of money that could be used to support such a multi-source funding. It will be used to 
approach philanthropic and public funding sources to support the demand for additional grants.





This policy governs the work of the experts when they review the projects of their colleagues.

Who Are the Experts on Crowdacure Peer Review Committee?


Ross Breckenridge


Ross studied Medical Sciences at Cambridge University, then qualified in clinical medicine from Oxford University Medical School. He completed a PhD in cardiac development at the Wellcome/CRUK Institute at Cambridge and went on to train in Clinical Pharmacology at University College London, where he is now a consultant physician and Director of the London Clinical Pharmacology Training Programme. Ross has 15 years experience as a consultant to investment funds. He currently sits on the Board of Directors of REVA Medical Inc., San Diego and Silver Creek Pharmaceuticals, San Francisco.

Diego Centonze


Diego Centonze is Full Professor of Neurology at the Department of Systems Medicine of the University of  Rome Tor Vergata and Head of the UOSD Multiple Sclerosis Clinical and Research Center at Tor Vergata Hospital. He leads the Laboratory for non-invasive brain stimulation at Tor Vergata Hospital, the Experimental Neurology Laboratory at Tor Vergata University and the Neuroimmunology and Synaptic Plasticity Laboratory at Fondazione Santa Lucia/CERC in Rome. His major clinical interest involves the evaluation of new drugs for the treatment of MS. His research interests are related to the role of synaptic transmission and plasticity in the pathophysiology of Multiple Sclerosis and of its experimental model, and to the physiology of the endocannabinoid system and its involvement in inflammatory neurodegenerative diseases. Prof. Centonze graduated in Medicine at the University of Rome La Sapienza in 1994, specialised in Neurology in 1999 and in Psychiatry in 2006 at the University of Rome Tor Vergata. He obtained his PhD in Rehabilitation Medicine in 2012. He is Principal Investigator of many phase II, III and IV national and international trials with new therapeutic agents for MS. He is also Expert Consultant of the European Medicine Agency for MS. He is Member of the Society for Neuroscience, the Italian Neurological Society (SIN) and the Italian Neuroscience Society (SINS). Prof. Centonze is author of around 290 peer-reviewed papers published in international journals of Neuroscience, Neurology and Psychiatry.

Cris Constantinescu


Cris Constantinescu graduated with an MD from Boston University School of Medicine in 1988 and then, as recipient of physician-scientist award from the National Institutes of Health, USA, completed a PhD in Immunology at the University of Pennsylvania in 1998, with a thesis exploring the role of IL-12 in immune responses in the central nervous system. He completed an internship, residency in Neurology and Fellowships in Neuroimmunology and Neurorehabilitation. He held positions in Neurology (MS Clinic) and Neurobiology at the University of Basel, Switzerland in 1997-1998 and in Immunology at the University of Leicester in 1999, United Kingdom, before being appointed Honorary Consultant Neurologist and Senior Lecturer in Neurology at University of Nottingham in 2000-2001. In 2004 he was appointed Chair in Neurology at University of Nottingham. His research interests are immune regulation in inflammatory diseases of the nervous system, in particular MS and its models, imaging in MS, clinical trials, and epidemiology. He runs a busy, large MS Clinic together with 4 other clinical neurologists in Nottingham. He is the clinical lead for neurological diseases in the East Midlands Clinical Research Network.

Gary Cutter


Gary Cutter, MS Ph.D. is a Professor of Biostatistics at the University of Alabama, Birmingham School of Public Health. He is an expert in clinical trials and epidemiologic studies. He has been Principal Investigator and has directed several coordinating, operations and data centres. He is a member of numerous data and safety monitoring committees and is on the editorial board of peer-reviewed journals. His focus of interest is Multiple Sclerosis, but he is active in many other fields of medicine.

Professor Gavin Giovannoni


Gavin Giovannoni was appointed to the Chair of Neurology, Barts and The London School of Medicine and Dentistry, in November 2006. Gavin did his undergraduate medical training in South Africa. He moved to the Institute of Neurology, Queen Square, in 1993 to do a PhD in Neuroimmunology. His clinical interests are multiple sclerosis and other inflammatory disorders of the central nervous system. His current research is focused on Epstein Barr virus as a possible cause of multiple sclerosis. April 2014

Professor Julian Gold


Julian Gold is a Professor at The Albion Centre, Prince of Wales Hospital, Sydney and at Queen Mary University of London, based at The Royal London Hospital, Whitechapel. He qualified in Medicine at University of Sydney and completed post-graduate training at University College Hospital, London School of Hygiene and Tropical Medicine and as an Epidemic Intelligence Service Officer at The U.S. Centers for Disease Control in Atlanta. His PhD thesis was on the epidemiology of HIV/AIDS in Australia where he established the original national AIDS surveillance system. Currently, he is a clinician and academic, managing patients with infectious diseases, and Director of the WHO Regional Collaborating Centre for HIV/AIDS, responsible for healthcare worker training and capacity building in Southeast Asia. His research interests, in addition to clinical trials of new anti-retroviral therapies for HIV, are in the possible viral aetiology of Multiple Sclerosis and the role of endogenous retroviruses as a cause or trigger for autoimmune diseases and some cancers. As principal investigator of the INSPIRE study, he co-leads a team to study the possible role of HIV anti-retroviral therapies as a treatment for Multiple Sclerosis. He divides his time between London and Sydney, much of which is spent at 35,000ft followed by extended periods of jet-lag. Professor Julian Gold MD FRSPH Director, The Albion Centre 150 Albion St Surry Hills, Sydney, NSW 2010 Australia.

Asma Khalil


Asma Khalil is a consultant obstetrician at St George's Hospital and honorary senior lecturer at St George's Medical School, University of London. She is a subspecialist in Maternal and Fetal Medicine. She is lead for the Multiple Pregnancy service at St George's Hospital, the referral unit for the South West London region. She gained her MD at the University of London in 2009. She also has a Masters degree in Epidemiology from the London School of Hygiene & Tropical Medicine and an MRC scholarship. She has published more than 70 peer reviewed papers, and many published review articles and chapters. She was awarded many research prizes, both at national and international meetings.

Mario Manto


Mario Manto is Neurologist and Researcher at the Free University of Brussels, Belgium. He is Professor of Neuroanatomy at the University of Mons, Belgium. He is the Founding Editor of the journal The Cerebellum (Springer) and the journal Cerebellum and Ataxias (BioMed Central). His research interest focuses on movement disorders. He has published 9 books and more than 150 papers in peer-reviewed journals.

Hugh Montgomery


Hugh Montgomery obtained a 1st Class BSc in Cardiorespiratory Physiology/ Neuropharmacology in 1984, and graduated from the Middlesex Hospital Medical School in 1987. He has since completed higher specialist training in Cardiology, General Internal Medicine and Intensive Care Medicine. He is Professor of Intensive Care Medicine at University College London, where he directs the Centre for Human Health and Performance. He has published over 280 scientific papers. He also works as a consultant intensivist at the Whittington Hospital in N London.
Toral Patel Member

DR, Toral Patel


Toral Patel, M.D., is an Assistant Professor of Neurological Surgery at UT Southwestern Medical Center, where she specializes in brain tumor surgery. Dr. Patel received her undergraduate degree in biomedical engineering from Johns Hopkins University and earned her medical degree at UT Southwestern Medical School. She completed a residency in neurological surgery at Yale-New Haven Hospital.  She then completed a fellowship in neurosurgical oncology at Memorial Sloan Kettering Cancer Center, before returning to UT Southwestern as a faculty member in 2014. Dr. Patel’s clinical and research interests are focused on the treatment of malignant brain tumors.  In particular, her research relates to the development of novel drug delivery systems for the central nervous system. Dr. Patel is a member of the Society for Neuro-Oncology, the Congress of Neurological Surgeons, and the American Association of Neurological Surgeons.

Bartlomiej Piechowski-Jozwiak


Bart is an active clinician and researcher in the field of Vascular Neurology. He graduated from the Medical University of Warsaw and he did several subseciatly fellowships in Vascular Neurology in leading Global Centres such as Helsinki University and Centre Hospitalier Universitaire Vaudois in Lausanne. He works as a consultant neurologist at King's College Hospital and he is an active member of Research Advisory Group for Neuroscience there and also a local Principal Investigator in Clinical Research Network studies. He has experience in openning research centres and implementing clinical research into daily clinical practice.

Hilla Shaviv


Hilla Shaviv is a  Bio-Fluid dynamics expert with over 15 years of experience developing medical devices. After having worked for several years as a R&D engineer in the bio-mechanical industry, changed gears to work on own inventions—currently the founder and CTO of GalMedics Biotech, a company focusing on the quality of life of menstruating women. The company is developing ActiLady, a tampon-like device that treats dysmenorrhea (menstrual pain). Hilla has followed the development of the device from its inception, fund raising, prototype design, through two clinical studies and regulation, to partnering with major industry players for the development of the market ready device. She obtained a B.Sc. in Mechanical & Fluid Dynamics Engineering, cum laude at Caltech and a Biomedical Engineering at Tel-Aviv University.

Olaf Stuve


Olaf Stuve is Chief of the Neurology Section, Veteran Affairs of the North Texas Health Care Systems, Medical Service and associate Professor, tenured, Department of Neurology, University of Texas Southwestern. He is also associate Professor, Graduate Program Immunology, University of Texas Southwestern Medical Center, Dallas, TX and Senior Lecturer, Department of Neurology, Heinrich Heine University Düsseldorf, Germany.

This is a unique website which will require a more modern browser to work! Please upgrade today!